Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.04 USD | +2.49% | +1.35% | +53.74% |
05-23 | Cogent Reports Positive Cancer Combo Treatment Trial Data; Names Commercial Chief | MT |
05-23 | Cogent Biosciences, Inc. Announces the Appointment of Cole Pinnow as Chief Commercial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.74% | 843M | |
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |
- Stock Market
- Equities
- COGT Stock
- News Cogent Biosciences, Inc.
- SVB Securities Adjusts Price Target on Cogent Biosciences to $20 From $18, Maintains Outperform Rating